Here are four things to know.
1. Vyzulta is a once-daily treatment to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
2. Valeant subsidiary Bausch + Lomb acquired the rights for the eye drug from Nicox, which will receive a $17.5 million milestone payment for the approval.
3. Valeant first submitted Vyzulta for regulatory approval more than two years ago, but the FDA rejected the drug due to various manufacturing issues.
4. The drugmaker expects Vyzulta to hit the market by the end of 2017.
More articles on supply chain:
6 ways the proposed Republican tax overhaul could impact pharma
2 Alere medical supply companies to close Florida facilities, lay off 182 employees
CVS Health sees operating income dip 11.5% due to reimbursement pressure, hurricanes
